Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 – GlobeNewswire

New York, March 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Therapy Industry" - https://www.reportlinker.com/p06033005/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Abstract: - Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - Amid the COVID-19 crisis, the global market for Stem Cell Therapy estimated at US$127.5 Million in the year 2020, is projected to reach a revised size of US$242.3 Million by 2027, growing at aCAGR of 9.6% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 9.9% CAGR and reach US$228.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Autologous segment is readjusted to a revised 5.6% CAGR for the next 7-year period. - The U.S. Market is Estimated at $37.8 Million, While China is Forecast to Grow at 9% CAGR - The Stem Cell Therapy market in the U.S. is estimated at US$37.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.9 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 33 Featured) -

Read the full report: https://www.reportlinker.com/p06033005/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Stem Cell Therapy Competitor Market Share Scenario Worldwide: ( in %): 2020E Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Cord Blood / Embryonic Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Market Facts & Figures Market Analytics Table 37: USA Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CANADA Table 46: Canada Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

JAPAN Table 55: Japan Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CHINA Table 64: China Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

EUROPE Market Facts & Figures Market Analytics Table 73: Europe Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

FRANCE Table 85: France Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

See the rest here:

Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - GlobeNewswire